This article was originally published in The Gray Sheet
Parkinson's disease control therapy system debuts in Europe following receipt of a CE mark, Medtronic reports April 27. The implantable neurostimulator is being marketed in Europe for use in stimulating the globus pallidus or subthalamic regions of the brain to control all major symptoms of Parkinson's disease, including rigidity, bradykinesia/akinesia, postural instability, and tremor. The Activa received FDA approval in July 1997 for stimulation of the thalamus to treat essential tremor and tremor associated with Parkinson's disease ("The Gray Sheet" Aug. 11, 1997, p. 5). Clinical evaluation in the U.S. for the expanded use is underway
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.